Literature DB >> 14679180

Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.

Feng-Chun Yang1, David A Ingram, Shi Chen, Cynthia M Hingtgen, Nancy Ratner, Kelly R Monk, Travis Clegg, Hilary White, Laura Mead, Mary Jo Wenning, David A Williams, Reuben Kapur, Simon J Atkinson, D Wade Clapp.   

Abstract

The NF1 tumor suppressor gene encodes a GTPase-activating protein called neurofibromin that negatively regulates Ras signaling. Mutations in NF1 cause neurofibromatosis type 1 (NF1). The development of neurofibromas, which are complex tumors composed of multiple cell types, is a hallmark of NF1. Somatic inactivation of murine Nf1 in Schwann cells is necessary, but not sufficient, to initiate neurofibroma formation. Neurofibromas occur with high penetrance in mice in which Nf1 is ablated in Schwann cells in the context of a heterozygous mutant (Nf1+/-) microenvironment. Mast cells infiltrate neurofibromas, where they secrete proteins that can remodel the ECM and initiate angiogenesis. Thus, identification of mechanisms responsible for mast cell migration to tumor microenvironments is important for understanding tumorigenesis and for designing potential therapies. Here, we show that homozygous Nf1 mutant (Nf1-/-) Schwann cells secrete Kit ligand (KitL), which stimulates mast cell migration, and that Nf1+/- mast cells are hypermotile in response to KitL. Furthermore, we link hyperactivation of the Ras-class IA-PI3K-Rac2 pathway to increased Nf1+/- mast cell migration. Thus, these studies identify a novel interaction between Nf1-/- Schwann cells and Nf1+/- mast cells that is likely to be important in neurofibroma formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679180      PMCID: PMC296994          DOI: 10.1172/JCI19195

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Differential requirements for alpha4 integrins during fetal and adult hematopoiesis.

Authors:  A G Arroyo; J T Yang; H Rayburn; R O Hynes
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

2.  Integrin activation by R-ras.

Authors:  Z Zhang; K Vuori; H Wang; J C Reed; E Ruoslahti
Journal:  Cell       Date:  1996-04-05       Impact factor: 41.582

3.  Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway.

Authors:  P E Hughes; M W Renshaw; M Pfaff; J Forsyth; V M Keivens; M A Schwartz; M H Ginsberg
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

Review 4.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.

Authors:  L C Cantley; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

5.  Enzyme histochemistry of tryptase in stomach mucosal mast cells of the mouse.

Authors:  K P Valchanov; G B Proctor
Journal:  J Histochem Cytochem       Date:  1999-05       Impact factor: 2.479

6.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis.

Authors:  L M Coussens; W W Raymond; G Bergers; M Laig-Webster; O Behrendtsen; Z Werb; G H Caughey; D Hanahan
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

7.  Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system.

Authors:  M Sondell; G Lundborg; M Kanje
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

8.  Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase.

Authors:  H A Kim; B Ling; N Ratner
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

9.  Analysis of vascularity of human neurofibromas.

Authors:  J L Arbiser; E Flynn; R L Barnhill
Journal:  J Am Acad Dermatol       Date:  1998-06       Impact factor: 11.527

10.  Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.

Authors:  A Klose; M R Ahmadian; M Schuelke; K Scheffzek; S Hoffmeyer; A Gewies; F Schmitz; D Kaufmann; H Peters; A Wittinghofer; P Nürnberg
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

View more
  79 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

3.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

4.  Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.

Authors:  Shi Chen; Sarah Burgin; Andrew McDaniel; Xiaohong Li; Jin Yuan; Mia Chen; Waleed Khalaf; D Wade Clapp; Feng-Chun Yang
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

5.  Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Authors:  Lu Q Le; Tracey Shipman; Dennis K Burns; Luis F Parada
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

6.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

7.  Interleukin 8/KC enhances G-CSF induced hematopoietic stem/progenitor cell mobilization in Fancg deficient mice.

Authors:  Yan Li; Wen Xing; Yong-Zheng He; Shi Chen; Steven D Rhodes; Jin Yuan; Yuan Zhou; Jun Shi; Jie Bai; Feng-Kui Zhang; Wei-Ping Yuan; Tao Cheng; Ming-Jiang Xu; Feng-Chun Yang
Journal:  Stem Cell Investig       Date:  2014-10-31

8.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

9.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

10.  Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation.

Authors:  B Bartelt-Kirbach; M Wuepping; M Dodrimont-Lattke; D Kaufmann
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.